

Andrea Conti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9502464/publications.pdf>

Version: 2024-02-01

103
papers

3,451
citations

201385

27
h-index

149479

56
g-index

105
all docs

105
docs citations

105
times ranked

3921
citing authors

#	ARTICLE	IF	CITATIONS
1	Does psoriasis influence female sexual dysfunction? A multicentric Italian case-control study. Italian Journal of Dermatology and Venereology, 2022, 157, .	0.1	2
2	Real-world evidence of biologic treatments in moderate-to-severe psoriasis in Italy: Results of the CANOVA (Effectiveness of biologic treatments for plaque) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	8
3	Efficacy and safety of guselkumab in two psoriatic patients with hepatitis B and C virus infection. Dermatologic Therapy, 2022, 35, e15281.	0.8	2
4	Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Italian Journal of Dermatology and Venereology, 2022, 157, 1-78.	0.1	25
5	Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience. Expert Opinion on Biological Therapy, 2022, 22, 1561-1566.	1.4	10
6	Phototherapy: The patients' point of view. Photodermatology Photoimmunology and Photomedicine, 2021, 37, 175-179.	0.7	2
7	Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study. Expert Opinion on Biological Therapy, 2021, 21, 271-277.	1.4	40
8	Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: ANorthern Italy experience. Journal of Allergy and Clinical Immunology, 2021, 147, 558-560.e1.	1.5	44
9	Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study. Acta Dermato-Venereologica, 2021, 101, adv00576.	0.6	5
10	Ixekizumab in hidradenitis suppurativa in a psoriatic patient. Giornale Italiano Di Dermatologia E Venereologia, 2021, 155, 788-789.	0.8	16
11	Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis. BioDrugs, 2021, 35, 469-471.	2.2	7
12	The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. Journal of the American Academy of Dermatology, 2021, 84, 1356-1363.	0.6	61
13	Dimethyl fumarate treatment for psoriasis in a real-life setting: A multicentric retrospective study. Dermatologic Therapy, 2021, 34, e15066.	0.8	16
14	Switching infliximab in psoriatic patients during COVID-19 pandemics: A real-life retrospective study comparing intra-versus interclass switching strategies. Dermatologic Therapy, 2021, 34, e15088.	0.8	6
15	Use of apremilast in the psoriasis treatment: a real-life multicentre Italian experience. Italian Journal of Dermatology and Venereology, 2021, , .	0.1	4
16	A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study. BMC Health Services Research, 2021, 21, 924.	0.9	6
17	Anti-drug antibody detection with label-free electrolyte-gated organic field-effect transistors. Chemical Communications, 2021, 57, 367-370.	2.2	20
18	Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics. European Journal of Dermatology, 2021, 31, 493-498.	0.3	2

#	ARTICLE	IF	CITATIONS
19	Moderate to severe psoriasis: a single-center analysis of gender prevalence. Italian Journal of Dermatology and Venereology, 2021, 156, 226-230.	0.1	3
20	Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Journal of Dermatological Treatment, 2020, 31, 476-483.	1.1	23
21	Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study. American Journal of Clinical Dermatology, 2020, 21, 441-447.	3.3	33
22	Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e770-e772.	1.3	31
23	Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS ONE, 2020, 15, e0237267.	1.1	19
24	COVID-19 and dermatology: a comprehensive guide for dermatologists. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1388-1394.	1.3	28
25	Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e360-e361.	1.3	41
26	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a real-world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845.	1.3	6
27	Biological therapy in psoriatic patients wishing fatherhood: a multicentre Italian experience in real life. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e468-e470.	1.3	1
28	Switching from one infliximab biosimilar (CTP13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. British Journal of Dermatology, 2020, 183, 397-398.	1.4	17
29	Consensus on the place in therapy of TNF inhibitors in the treatment of patients with chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e470-e472.	1.3	6
30	Combination treatment with secukinumab and dimethyl fumarate in a patient with psoriasis and recent diagnosis of multiple sclerosis. Dermatologic Therapy, 2020, 33, e13943.	0.8	6
31	The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. British Journal of Dermatology, 2020, 183, 373-374.	1.4	104
32	Chronic kidney disease in psoriasis: a cohort study. JDDG - Journal of the German Society of Dermatology, 2020, 18, 438-445.	0.4	11
33	Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1196-1201.	1.3	85
34	TNF inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. Expert Review of Clinical Immunology, 2020, 16, 591-598.	1.3	18
35	Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients. European Journal of Dermatology, 2020, 30, 159-164.	0.3	2
36	A real-life experience of psoriatic patients with history of cancer treated with biological drugs. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e453-e455.	1.3	11

#	ARTICLE	IF	CITATIONS
37	Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 273-275.	0.6	39
38	Psoriasis and pregnancy outcomes in biological therapies: a real-life, multi-centre experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e374-e377.	1.3	17
39	Pruritus characteristics in a large Italian cohort of psoriatic patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1316-1324.	1.3	46
40	Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience. <i>Dermatology</i> , 2019, 235, 213-218.	0.9	9
41	Etanercept biosimilar <sc>SB</sc> 4 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. <i>British Journal of Dermatology</i> , 2019, 180, 409-410.	1.4	17
42	Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. <i>British Journal of Dermatology</i> , 2019, 180, 1547-1548.	1.4	30
43	Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. <i>Breast Cancer</i> , 2019, 26, 520-523.	1.3	6
44	Evaluation of generalized pustular psoriasis by reflectance confocal microscopy. <i>Skin Research and Technology</i> , 2019, 25, 402-403.	0.8	2
45	Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019, 154, 376-377.	0.8	3
46	Seminal cell-free DNA molecular profile as a novel diagnostic and prognostic prostate cancer biomarkers. <i>Medical Hypotheses</i> , 2018, 114, 69.	0.8	4
47	Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection. <i>Dermatologic Therapy</i> , 2018, 31, e12601.	0.8	9
48	Secukinumab in multi-failure psoriatic patients: the last hope?. <i>Journal of Dermatological Treatment</i> , 2018, 29, 583-585.	1.1	14
49	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	1.3	15
50	Ineffectiveness of infliximab CT&P13 for the treatment of scleromyxedema: A case report. <i>Dermatologic Therapy</i> , 2018, 31, e12583.	0.8	5
51	Psoriasis improvement after gastric bandage in a patient partial responder to infliximab. <i>Dermatologic Therapy</i> , 2018, 31, e12584.	0.8	1
52	Non-invasive evaluation of Secukinumab efficacy in severe plaque psoriasis with confocal microscopy and optical coherence tomography: A case report. <i>Skin Research and Technology</i> , 2018, 24, 160-162.	0.8	12
53	Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. <i>Journal of Dermatological Treatment</i> , 2018, 29, 5-8.	1.1	11
54	Seminal Cell Free DNA Concentration Levels Discriminate Between Prostate Cancer and Benign Prostatic Hyperplasia. <i>Anticancer Research</i> , 2018, 38, 5121-5125.	0.5	17

#	ARTICLE	IF	CITATIONS
55	Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines. Italian Journal of Dermatology and Venereology, 2018, 153, 305-315.	0.1	8
56	How to improve adherence to treatment in patients with mild-to-moderate psoriasis. Giornale Italiano Di Dermatologia E Venereologia, 2018, 153, 692-697.	0.8	7
57	Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1853-1859.	1.3	27
58	Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 863-869.	1.3	31
59	Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 774-790.	1.3	140
60	Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry. British Journal of Dermatology, 2017, 177, e325-e326.	1.4	19
61	Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. Dermatologic Therapy, 2017, 30, e12503.	0.8	10
62	Clinical features and in vivo reflectance confocal microscopy of an atypical presentation of Herpesvirus-2 and Cytomegalovirus co-infection of the intergluteal sulcus. Skin Research and Technology, 2017, 23, 619-620.	0.8	2
63	Efficacy of ustekinumab after failure of infliximab <sc>CT</sc>-P13 in a <sc>HLA</sc>-Cw6-positive patient affected by pityriasis rubra pilaris: monitoring with reflectance confocal microscopy (<sc>RCM</sc>) and optical coherence tomography (<sc>OCT</sc>). Journal of the European Academy of Dermatology and Venereology, 2017, 31, e249-e251.	1.3	10
64	Down-titration of Adalimumab and Etanercept in Psoriatic Patients: A Multicentre Observational Study. Acta Dermato-Venereologica, 2016, 96, 251-252.	0.6	21
65	Long-term efficacy of high doses of intravenous immunoglobulins in generalized scleromyxoedema: Case report. Journal of International Medical Research, 2016, 44, 109-112.	0.4	7
66	Speckled variance optical coherence tomography for the assessment of nail involvement in acrodermatitis continua of Hallopeau: A case study. Journal of International Medical Research, 2016, 44, 119-123.	0.4	6
67	Psoriasis awareness among Italian patients: results of a nationwide survey. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 1-8.	0.8	9
68	Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. British Journal of Dermatology, 2015, 172, 1613-1620.	1.4	36
69	Reflectance confocal microscopy for plaque psoriasis therapeutic follow-up during an anti-<sc>TNF</sc>-monoclonal antibody: an observational multicenter study. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2363-2368.	1.3	20
70	<sc>PSOCUBE</sc>, a multidimensional assessment of psoriasis patients as a both clinically/practically sustainable and evidence-based algorithm. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1310-1317.	1.3	8
71	Validation and Field Performance of the Italian Version of the Psoriatic Arthritis Screening and Evaluation (PASE) Questionnaire. Acta Dermato-Venereologica, 2014, 96, 96-101.	0.6	4
72	Efficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients. Acta Dermato-Venereologica, 2014, 94, 293-297.	0.6	71

#	ARTICLE	IF	CITATIONS
73	Monoclonal Gammopathy of Undetermined Significance in Patients with Psoriasis: Is it Really a Side Effect of Biological Therapy?. Drug Development Research, 2014, 75, S35-7.	1.4	6
74	Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF- β 2 signalling in modifying disease severity. Human Molecular Genetics, 2014, 23, 3907-3922.	1.4	88
75	Efficacy of switching between tumor necrosis factor- α inhibitors in psoriasis: Results from the Italian Psocare Registry. Journal of the American Academy of Dermatology, 2014, 70, 257-262.e3.	0.6	54
76	Management of Patients with Psoriasis Treated with Biological Drugs Needing a Surgical Treatment. Drug Development Research, 2014, 75, S24-S26.	1.4	19
77	Comments on "Diet and psoriasis, part I: Impact of weight loss interventions" Journal of the American Academy of Dermatology, 2014, 71, 829.	0.6	0
78	Diet and physical exercise in psoriasis: a randomized controlled trial. British Journal of Dermatology, 2014, 170, 634-642.	1.4	146
79	Skeletal and cranio-facial signs in Gorlin syndrome from ancient Egypt to the modern age: sphenoid asymmetry in a patient with a novel <i>PTCH1</i> mutation. Future Oncology, 2014, 10, 917-925.	1.1	3
80	Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. European Review for Medical and Pharmacological Sciences, 2014, 18, 3435-52.	0.5	3
81	Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e30-41.	1.3	75
82	Detection and management of latent tuberculosis infections before biologic therapy for psoriasis. Journal of Dermatological Treatment, 2013, 24, 305-311.	1.1	28
83	Psoriasis plaque test with confocal microscopy: evaluation of different microscopic response pathways in NSAID and steroid treated lesions. Skin Research and Technology, 2013, 19, 417-423.	0.8	26
84	Immunogenicity of anti-TNF \pm therapy in psoriasis: a clinical issue?. Expert Opinion on Biological Therapy, 2013, 13, 1673-1682.	1.4	56
85	The somatic affairs of <i>BRAF</i> : tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations. Journal of Clinical Pathology, 2013, 66, 441-445.	1.0	21
86	Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. British Journal of Dermatology, 2013, 168, 1124-1127.	1.4	67
87	Efficacy of etanercept for the treatment of psoriasis: an overview of the Italian clinical experience from the real-life setting and independent studies. Immunopharmacology and Immunotoxicology, 2012, 34, 901-906.	1.1	3
88	Psodisk, a new visual method for assessing the burden of psoriasis on patients. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 1163-1166.	1.3	26
89	Annular Lichenoid Dermatitis of Youth and Beyond: A Series of 6 Cases. American Journal of Dermatopathology, 2009, 31, 263-267.	0.3	34
90	Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. British Journal of Dermatology, 2007, 157, 68-73.	1.4	543

#	ARTICLE	IF	CITATIONS
91	Cutaneous metastases as the first manifestation of pleural malignant mesothelioma. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 363-365.	0.6	22
92	Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. <i>Nature Medicine</i> , 2006, 12, 1397-1402.	15.2	593
93	725. Correction of Laminin-5-Deficient Junctional Epidermolysis Bullosa by Transplantation of Genetically Modified Epidermal Stem Cells. A Phase-I Clinical Trial. <i>Molecular Therapy</i> , 2006, 13, S280.	3.7	0
94	No Increased Skin Reactivity in Subjects with Allergic Rhinitis During the Active Phase of the Disease: Clinical Report. <i>Acta Dermato-Venereologica</i> , 2000, 80, 192-195.	0.6	14
95	TOTAL HIP DISARTICULATION PROSTHESIS WITH SUCTION SOCKET. <i>American Journal of Physical Medicine and Rehabilitation</i> , 1999, 78, 160-162.	0.7	19
96	In vivo assessment of n-alkyl-sulfate-induced skin irritation by means of non-invasive methods. <i>Skin Research and Technology</i> , 1998, 4, 192-195.	0.8	5
97	P137 Erosive pustular dermatosis of the scalp: A case report. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1997, 9, S185.	1.3	0
98	Contact sensitization to preservatives in children. <i>Contact Dermatitis</i> , 1997, 37, 35-36.	0.8	26
99	No Alteration of Biophysical Parameters in the Skin of Subjects with Respiratory Atopy. <i>Dermatology</i> , 1996, 192, 317-320.	0.9	35
100	Sensitization to reactive textile dyes in patients with contact dermatitis. <i>Contact Dermatitis</i> , 1996, 34, 172-175.	0.8	43
101	Sensitization to white petrolatum used as a vehicle for patch testing. <i>Contact Dermatitis</i> , 1995, 33, 201-202.	0.8	15
102	Capacitance, transepidermal water loss and causal level of sebum in healthy subjects in relation to site, sex and age. <i>International Journal of Cosmetic Science</i> , 1995, 17, 77-85.	1.2	60
103	Quantitative description of echographic images of morphea plaques as assessed by computerized image analysis on 20 MHz B-scan recordings.. <i>Acta Dermato-Venereologica</i> , 1995, 75, 442-445.	0.6	7